| 2020 |
Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body J-J, Minisola S. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone. January 2020;130:115113. |
0 |
0 |
| 2021 |
Cappelle S, Moreau M, Karmali R, Iconaru L, Baleanu F, Kinnard V, Paesmans M, Rozenberg S, Rubinstein M, Surquin M, Blard P-H, Chapurlat R, Body JJ, Bergmann P. Discriminating value of HR-pQCT for fractures in women with similar FRAX scores: a substudy of the FRISBEE cohort. Bone. February 2021;143:115613. |
2 |
2 |
| 2022 |
Paccou J, Tsourdi E, Meier C, Palermo A, Pepe J, Body J-J, Zillikens MC. Bariatric surgery and skeletal health: a narrative review and position statement for management by the European Calcified Tissue Society (ECTS). Bone. January 2022;154:116236. |
0 |
0 |
| 2020 |
Kinnard V, Baleanu F, Iconaru L, Moreau M, Paesmans M, Body J, Bergmann P. Postfracture risk assessment: target the centrally sited fractures first! a substudy of NoFRACT. J Bone Miner Res. April 2020;35(4):827-828. |
1 |
0 |
| 2022 |
Iconaru L, Charles A, Baleanu F, Surquin M, Benoit F, Mugisha A, Moreau M, Paesmans M, Karmali R, Rubinstein M, Rozenberg S, Body J-J, Bergmann P. Prediction of an imminent fracture after an index fracture: models derived from the Frisbee cohort. J Bone Miner Res. January 2022;37(1):59-67. |
0 |
0 |
| 2010 |
Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, Lichinitser RH, de Boer M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. December 10, 2010;28(35):5132-5139. |
21 |
21 |
| 2018 |
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240. |
29 |
24 |
| 2020 |
Iconaru L, Smeys C, Baleanu F, Kinnard V, Moreau M, Cappelle S, Surquin M, Rubinstein M, Rozenberg S, Paesmans M, Karmali R, Bergmann P, Body JJ. Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int. July 2020;31(7):1377-1382. |
1 |
1 |
| 2020 |
Body J-J, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. October 2020;31(10):1935-1942. |
0 |
0 |